Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 2, 2012, Pages 111-125

  Kelesidis, Theodoros ^a   Pothoulakis, Charalabos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efficacy; Gastrointestinal disorders; Probiotic; Saccharomyces boulardii; Safety

Indexed keywords

FLUCONAZOLE; MEBEVERINE; MESALAZINE; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT;

ACUTE DIARRHEA; ADAPTIVE IMMUNITY; AIR POLLUTION; ALLERGIC REACTION; AMEBIASIS; BACTERIAL TRANSLOCATION; BLASTOCYSTOSIS; CHOLERA; CHRONIC DIARRHEA; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; ENTERIC FEEDING; ENTERITIS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI; ENVIRONMENTAL DISEASE; ENZYME ACTIVITY; ERADICATION THERAPY; FUNGEMIA; GIARDIASIS; HELICOBACTER INFECTION; HOMEOSTASIS AND REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INDWELLING CATHETER; INNATE IMMUNITY; INTESTINE MUCOSA; IRRITABLE COLON; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; NECROTIZING ENTEROCOLITIS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; TARGET ORGAN; TRAVELLER DIARRHEA; ULCERATIVE COLITIS;

EID: 84857520779     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11428502     Document Type: Review

References (134)

1. Barc M.C. Charrin-Sarnel C. Rochet V. Bourlioux F. Sandre C. Boureau H. et al. (2008) Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe 14: 229–233.
2. Bartlett J.G. (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346: 334–339.
3. Bennani A. (1990) Randomised trial of Saccharomyces boulardii in the treatment of functional colon disorders. L'Objectif Medical 73: 56–61.
4. Besirbellioglu B.A. Ulcay A. Can M. Erdem H. Tanyuksel M. Avci I.Y. et al. (2006) Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis 38: 479–481.
5. Billoo A.G. Memon M.A. Khaskheli S.A. Murtaza G. Iqbal K. Saeed S.M. et al. (2006) Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 12: 4557–4560.
6. Bisson J.F. Hidalgo S. Rozan P. Messaoudi M. (2010) Preventive effects of different probiotic formulations on travelers’ diarrhea model in Wistar rats: preventive effects of probiotics on TD. Dig Dis Sci 55: 911–919.
7. Blehaut H. Massot J. Elmer G.W. Levy R.H. (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10: 353–364.
8. Bleichner G. Blehaut H. Mentec H. Moyse D. (1997) Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 23: 517–523.
9. Brandao R.L. Castro I.M. Bambirra E.A. Amaral S.C. Fietto L.G. Tropia M.J. et al. (1998) Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 64: 564–568.
10. Breves G. Faul K. Schroder B. Holst H. Caspary W.F. Stein J. (2000) Application of the colon-simulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. Digestion 61: 193–200.
11. Burkhardt O. Kohnlein T. Pletz M. Welte T. (2005) Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 37: 69–72.
12. Buts J.P. (2009) Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 54: 15–18.
13. Buts J.P. Bernasconi P. Vaerman J.P. Dive C. (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35: 251–256.
14. Buts J.P. Bernasconi P. van Craynest M.P. Maldague P. De M.R. (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20: 192–196.
15. Buts J.P. Corthier G. Delmee M. (1993) Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 16: 419–425.
16. Buts J.P. De K.N. De R.L. (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36: 522–527.
17. Buts J.P. De K.N. Marandi S. Hermans D. Sokal E.M. Chae Y.H. et al. (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45: 89–96.
18. Buts J.P. De K.N. Stilmant C. Sokal E. Marandi S. (2002) Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res 51: 528–534.
19. Buts J.P. Dekeyser N. Stilmant C. Delem E. Smets F. Sokal E. (2006) Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 60: 24–29.
20. Buts J.P. Duranton B. De K.N. Sokal E.M. Maernhout A.S. Raul F. et al. (1998) Premature stimulation of rat sucrase-isomaltase (SI) by exogenous insulin and the analog B-Asp10 is regulated by a receptor-mediated signal triggering SI gene transcription. Pediatr Res 43: 585–591.
21. Caetano J.A. Parames M.T. Babo M.J. Santos A. Ferreira A.B. Freitas A.A. et al. (1986) Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 8: 245–259.
22. Cain A.M. Karpa K.D. (2011) Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med 17: 72–79.
23. Can M. Besirbellioglu B.A. Avci I.Y. Beker C.M. Pahsa A. (2006) Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 12: I19-I22.
24. Canani R.B. Cirillo P. Terrin G. Cesarano L. Spagnuolo M.I. De V.A. et al. (2007) Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 335: 340.
25. Canil C. Rosenshine I. Ruschkowski S. Donnenberg M.S. Kaper J.B. Finlay B.B. (1993) Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun 61: 2755–2762.
26. Canonici A. Siret C. Pellegrino E. Pontier-Bres R. Pouyet L. Montero M.P. et al. (2011) Saccharomyces boulardii improves intestinal cell restitution through activation of the alpha2beta1 integrin collagen receptor. PloS ONE 6: e18427.
27. Castagliuolo I. La Mont J.T. Nikulasson S.T. Pothoulakis C. (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64: 5225–5232.
28. Castagliuolo I. Riegler M.F. Valenick L. La Mont J.T. Pothoulakis C. (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67: 302–307.
29. Castaneda C. Garcia E. Santa Cruz M. Fernandez M. Monterrey P. (1995) Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr 2: 12–16.
30. Castex F. Corthier G. Jouvert S. Elmer G.W. Lucas F. Bastide M. (1990) Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. J Gen Microbiol 136: 1085–1089.
31. Chen X. Kokkotou E.G. Mustafa N. Bhaskar K.R. Sougioultzis S. O'Brien M. et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449–24454.
32. Choi C.H. Jo S.Y. Park H.J. Chang S.K. Byeon J.S. Myung S.J. (2011) A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol, in press.
33. Cindoruk M. Erkan G. Karakan T. Dursun A. Unal S. (2007) Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12: 309–316.
34. Cohen S.H. Gerding D.N. Johnson S. Kelly C.P. Loo V.G. McDonald L.C. et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431–455.
35. Cremonini F. Di C.S. Covino M. Armuzzi A. Gabrielli M. Santarelli L. et al. (2002) Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97: 2744–2749.
36. Czerucka D. Dahan S. Mograbi B. Rossi B. Rampal P. (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T 84 cells. Infect Immun 68: 5998–6004.
37. Czerucka D. Piche T. Rampal P. (2007) Review article: yeast as probiotics – Saccharomyces boulardii. Aliment Pharmacol Ther 26: 767–778.
38. Czerucka D. Rampal P. (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4: 733–739.
39. Czerucka D. Roux I. Rampal P. (1994) Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3’,5’-cyclic monophosphate induction in intestinal cells. Gastroenterology 106: 65–72.
40. Dahan S. Busuttil V. Imbert V. Peyron J.F. Rampal P. Czerucka D. (2002) Enterohemorrhagic Escherichia coli infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappa B and AP-1 in T 84 cells. Infect Immun 70: 2304–2310.
41. Dahan S. Dalmasso G. Imbert V. Peyron J.F. Rampal P. Czerucka D. (2003) Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T 84 cells. Infect Immun 71:766–773.
42. Dalmasso G. Cottrez F. Imbert V. Lagadec P. Peyron J.F. Rampal P. et al. (2006 a) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131: 1812–1825.
43. Dalmasso G. Loubat A. Dahan S. Calle G. Rampal P. Czerucka D. (2006 b) Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T 84 cells. Res Microbiol 157: 456–465.
44. Dinleyici E.C. Eren M. Dogan N. Reyhanioglu S. Yargic Z.A. Vandenplas Y. (2011) Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res 108: 541–545.
45. Dinleyici E.C. Eren M. Yargic Z.A. Dogan N. Vandenplas Y. (2009) Clinical efficacy of Saccharomyces boulardii and metronidazole compared with metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. Am J Trop Med Hyg 80: 953–955.
46. Duman D.G. Bor S. Ozutemiz O. Sahin T. Oguz D. Istan F. et al. (2005) Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 17: 1357–1361.
47. Elmer G.W. Corthier G. (1991) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol 37: 315–317.
48. Elmer G.W. Martin S.W. Horner K.L. McFarland L.V. Levy R.H. (1999 a) Survival of Saccharomyces boulardii in the rat gastrointestinal tract and effects of dietary fiber. Microb Ecology Health Dis 11: 29–34.
49. Elmer G.W. McFarland L.V. Surawicz C.M. Danko L. Greenberg R.N. (1999 b) Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13: 1663–1668.
50. Elmer G.W. Moyer K.A. Vega R. Surawicz C.M. Collier A.C. Hooton T.M. et al. (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microb Ther 25: 23–31.
51. Fidan I. Kalkanci A. Yesilyurt E. Yalcin B. Erdal B. Kustimur S. et al. (2009) Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses 52: 29–34.
52. Floch M.H. Walker W.A. Guandalini S. Hibberd P. Gorbach S. Surawicz C. et al. (2008) Recommendations for probiotic use–2008. J Clin Gastroenterol 42(Suppl. 2): S104-S108.
53. Gaon D. Garcia H. Winter L. (2003) Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 63: 293–298.
54. Garcia V.E. de Lourdes D.e. Abreu F. Oswaldo D.a. Gama T.H. Guerra P.A. Carolina Carneiro A.A. Paiva M.F. et al. (2008) Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 43: 842–848.
55. Gareau M.G. Sherman P.M. Walker W.A. (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7: 503–514.
56. Gedek B.R. (1999 a) Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42: 261–264.
57. Gedek B.R. (1999 b) Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42: 261–264.
58. Generoso S.V. Viana M.L. Santos R.G. Arantes R.M. Martins F.S. Nicoli J.R. et al. (2011) Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr 50: 261–269.
59. Geyik M.F. Aldemir M. Hosoglu S. Ayaz C. Satilmis S. Buyukbayram H. et al. (2006) The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl 88: 176–180.
60. Girard P. Pansart Y. Gillardin J.M. (2005) Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats. Nitric Oxide 13: 163–169.
61. Gorbach S.L. (2000) Probiotics and gastrointestinal health. Am J Gastroenterol 95: S2-S4.
62. Gotteland M. Poliak L. Cruchet S. Brunser O. (2005) Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 94: 1747–1751.
63. Graff S. Chaumeil J.C. Boy P. Lai-Kuen R. Charrueau C. (2008 a) Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition. Biol Pharm Bull 31: 266–272.
64. Graff S. Chaumeil J.C. Boy P. Lai-Kuen R. Charrueau C. (2008 b) Influence of pH conditions on the viability of Saccharomyces boulardii yeast. J Gen Appl Microbiol 54: 221–227.
65. Guarino A. Albano F. Ashkenazi S. Gendrel D. Hoekstra J.H. Shamir R. et al. (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 46(Suppl. 2): S81–S122.
66. Guslandi M. (2010) Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol 44:385.
67. Guslandi M. (2011) Treatment of irritable bowel syndrome with Saccharomyces boulardii. J Clin Gastroenterol, in press.
68. Guslandi M. Giollo P. Testoni P.A. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 697–698.
69. Guslandi M. Mezzi G. Sorghi M. Testoni P.A. (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45: 1462–1464.
70. Hennequin C. Kauffmann-Lacroix C. Jobert A. Viard J.P. Ricour C. Jacquemin J.L. et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19: 16–20.
71. Herek O. Kara I.G. Kaleli I. (2004) Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34: 256–260.
72. Hochter W. Chase D. Hagenhoff G. (1990) Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wschr 132: 188–192.
73. Htwe K. Yee K.S. Tin M. Vandenplas Y. (2008) Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 78: 214–216.
74. Hurduc V. Plesca D. Dragomir D. Sajin M. Vandenplas Y. (2009) A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr 98: 127–131.
75. Hwang J.B. Kang K.J. Kang Y.N. Kim A.S. (2009) Probiotic gastrointestinal allergic reaction caused by Saccharomyces boulardii. Ann Allergy Asthma Immunol 103: 87–88.
76. Im E. Pothoulakis C. (2010) [Recent advances in Saccharomyces boulardii research]. Gastroenterol Clin Biol 34(Suppl. 1): S62–S70.
77. Jahn H.U. Ullrich R. Schneider T. Liehr R.M. Schieferdecker H.L. Holst H. et al. (1996) Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57: 95–104.
78. Kajander K. Myllyluoma E. Rajilic-Stojanovic M. Kyronpalo S. Rasmussen M. Jarvenpaa S. et al. (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27: 48–57.
79. Klein S.M. Elmer G.W. McFarland L.V. Surawicz C.M. Levy R.H. (1993) Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10: 1615–1619.
80. Kollaritsch H. Holst H. Grobara P. Wiedermann G. (1993) [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med 111: 152–156.
81. Kollaritsch H. Kremsner P. Wiedermann G. Scheiner O. (1989) Prevention of traveller's diarrhea: comparison of different non-antibiotic preparations. Travel Med Internat 7: 9–18.
82. Kotowska M. Albrecht P. Szajewska H. (2005) Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21: 583–590.
83. Kurugol Z. Koturoglu G. (2005) Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 94: 44–47.
84. Kyne L. Warny M. Qamar A. Kelly C.P. (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357: 189–193.
85. Lee S.K. Kim H.J. Chi S.G. Jang J.Y. Nam K.D. Kim N.H. et al. (2005) [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells]. Korean J Gastroenterol 45: 328–334.
86. Lee S.K. Kim Y.W. Chi S.G. Joo Y.S. Kim H.J. (2009) The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54: 255–263.
87. Mansour-Ghanaei F. Dehbashi N. Yazdanparast K. Shafaghi A. (2003) Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol 9: 1832–1833.
88. Marcobal A. Underwood M.A. Mills D.A. (2008) Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr 46: 608–611.
89. Martins F.S. Nardi R.M. Arantes R.M. Rosa C.A. Neves M.J. Nicoli J.R. (2005) Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51: 83–92.
90. Martins F.S. Veloso L.C. Arantes R.M. Nicoli J.R. (2009) Effects of yeast probiotic formulation on viability, revival and protection against infection with Salmonella enterica ssp. enterica serovar Typhimurium in mice. Lett Appl Microbiol 49: 738–744.
91. Masco L. Huys G. de B.E. Temmerman R. Swings J. (2005) Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 102: 221–230.
92. Maupas J.L. Champemont P. Delforge M. (1983) Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled study. Med Chir Dig 12: 77–79.
93. McFarland L.V. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812–822.
94. McFarland L.V. (2007) Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 5: 97–105.
95. McFarland L.V. (2009) Unraveling the causes of negative studies: a case of S boulardii for the prevention of antibiotic-associated diarrhea. Rev Med Chil 137: 719–720.
96. McFarland L.V. (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202–2222.
97. McFarland L.V. Dublin S. (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14: 2650–2661.
98. McFarland L.V. Surawicz C.M. Greenberg R.N. Fekety R. Elmer G.W. Moyer K.A. et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913–1918.
99. Mumy K.L. Chen X. Kelly C.P. McCormick B.A. (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294: G599–G609.
100. Pant N. Marcotte H. Brussow H. Svensson L. Hammarstrom L. (2007) Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol 7: 86.
101. Parkes G.C. Brostoff J. Whelan K. Sanderson J.D. (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103: 1557–1567.
102. Plein K. Hotz J. (1993) Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea–a pilot study. Z Gastroenterol 31: 129–134.
103. Pothoulakis C. (2009) Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 30: 826–833.
104. Pothoulakis C. Kelly C.P. Joshi M.A. Gao N. O'Keane C.J. Castagliuolo I. et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104: 1108–1115.
105. Qamar A. Aboudola S. Warny M. Michetti P. Pothoulakis C. La Mont J.T. et al. (2001) Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69: 2762–2765.
106. Rigothier M.C. Maccario J. Gayral P. (1994) Inhibitory activity of saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res 80: 10–15.
107. Rodrigues A.C. Cara D.C. Fretez S.H. Cunha F.Q. Vieira E.C. Nicoli J.R. et al. (2000) Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89: 404–414.
108. Rodrigues A.C. Nardi R.M. Bambirra E.A. Vieira E.C. Nicoli J.R. (1996) Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81: 251–256.
109. Saint-Marc T. Rossello-Prats L. Touraine J.L. (1991) [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS]. Ann Med Interne (Paris) 142: 64–65.
110. Schlotterer M. Bernasconi P. Le Breton F. Wassermann D. (1987) Value of Saccharomyces boulardii in the digestive acceptability of continuous-flow enteral nutrition in burnt patients. Nutr Clin Metabol 1: 31–34.
111. Schneider S.M. Girard-Pipau F. Filippi J. Hebuterne X. Moyse D. Hinojosa G.C. et al. (2005) Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11: 6165–6169.
112. Schwenzer V.B. (1998) Saccharomyces boulardii. Deutsche Apotheker Zeitung 138: 75–77.
113. Sezer A. Usta U. Cicin I. (2009) The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 26: 350–357.
114. Sougioultzis S. Simeonidis S. Bhaskar K.R. Chen X. Anton P.M. Keates S. et al. (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappa B-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69–76.
115. Surawicz C.M. McFarland L.V. Greenberg R.N. Rubin M. Fekety R. Mulligan M.E. et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012–1017.
116. Swidsinski A. Loening-Baucke V. Verstraelen H. Osowska S. Doerffel Y. (2008) Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 135: 568–579.
117. Szajewska H. Horvath A. Piwowarczyk A. (2010) Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32: 1069–1079.
118. Szajewska H. Mrukowicz J. (2005) Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 22: 365–372.
119. Szajewska H. Setty M. Mrukowicz J. Guandalini S. (2006) Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 42: 454–475.
120. Szajewska H. Skorka A. (2009) Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther 30: 960–961.
121. Szajewska H. Skorka A. Dylag M. (2007) Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 25: 257–264.
122. Tasteyre A. Barc M.C. Karjalainen T. Bourlioux P. Collignon A. (2002) Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 32: 219–225.
123. Tempe J.D. Steidel A.L. Blehaut H. Hasselmann M. Lutun P. Maurier F. (1983) [Prevention of diarrhea administering Saccharomyces boulardii during continuous enteral feeding]. Sem Hop 59: 1409–1412.
124. Thomas S. Przesdzing I. Metzke D. Schmitz J. Radbruch A. Baumgart D.C. (2009) Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol 156: 78–87.
125. Tong J.L. Ran Z.H. Shen J. Zhang C.X. Xiao S.D. (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25: 155–168.
126. Toothaker R.D. Elmer G.W. (1984) Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother 26: 552–556.
127. Vandenplas Y. Brunser O. Szajewska H. (2009) Saccharomyces boulardii in childhood. Eur J Pediatr 168: 253–265.
128. Venugopalan V. Shriner K.A. Wong-Beringer A. (2010) Regulatory oversight and safety of probiotic use. Emerg Infect Dis 16: 1661–1665.
129. Vidon N. Huchet B. Rambaud J.C. (1986) [Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin]. Gastroenterol Clin Biol 10: 13–16.
130. Villarruel G. Rubio D.M. Lopez F. Cintioni J. Gurevech R. Romero G. et al. (2007) Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr 96: 538–541.
131. Weese J.S. (2003) Evaluation of deficiencies in labeling of commercial probiotics. Can Vet J 44: 982–983.
132. Whelan K. Myers C.E. (2010) Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 91: 687–703.
133. Wu X. Vallance B.A. Boyer L. Bergstrom K.S. Walker J. Madsen K. et al. (2008) Saccharomyces boulardii ameliorates Citrobacter rodentium- induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 294: G295-G306.
134. Zanello G. Meurens F. Berri M. Salmon H. (2009) Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol 11: 47–58.